65--Sterile Compounding Pharmaceutical VA261-17-AP-11355

THIS IS A SOURCES SOUGHT NOTICE (a) The Government does not intend to award a contract on the basis of this Sources Sought or to otherwise pay for the information solicited. (b) Although proposal, offeror, contractor, and offeror may be used in this sources sought notice, any response will be treated as information only. It shall not be used as a proposal. (c) Any information received from a contractor in response to this Sources Sought may be used in creating a solicitation. Any information received which is marked with a statement, such as proprietary or confidential, intended to restrict distribution will not be distributed outside of the Government, except as required by law. (d) This Sources Sought is issued for the purpose of collecting information about the availability of equal products from different sources for the desired equipment listed in the Price-Cost Schedule that meets the corresponding Salient Characteristics. (e) Contractors that feel they have an equal product are encouraged to email full information to Veronica Gomez at [email protected]. Contractors shall identify the NAICS code for the product being offered as well as their size status. Contractors shall complete the Price-Cost Schedule for the purpose of market research. Contractors shall include the terms and conditions of the warranty for all proposed equal product. SALIENT CHARACTERISTICS: The following salient characteristics are essential, significant and functional to the Government s requirements: MUST BE 0.2% ROPIVACAINE HCI INJECTION MUST HAVE ON-Q PAIN RELIEF SYSTEM (400ML WITH MAX FLOW OF 550ML) SHALL HAVE A SELECT-A-FLOW VARIABLE CONTROLLER (WHITE 2,4,6,8,10,12,14 ML/HR) MUST HAVE ONDEMAND BOLUS BUTTON (5ML/30MIN) SHALL INCLUDE CARRYING POUCH MUST BE PREPARED BY 503B FDA CERTIFIED COMPOUNDING FACILITY